Q2040 HCPCS Level II code: Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
CMS terminated Q2040: its last date of service was Dec 31, 2018. It stays here for looking up older claims; newer services need a current code.
Official description
Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Short description: Tisagenlecleucel car-pos t
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2040 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Jan 1, 2018
- Terminated after
- Dec 31, 2018
Where Q2040 sits
- 1Q codesTemporary codes
- 2Terminated Q2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q2040 still valid?
No. CMS terminated Q2040; its last date of service was Dec 31, 2018. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q2040?
CMS lists Q2040’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2040
All Q codesQ2034Influenza virus vaccine, split virus, for intramuscular use (agriflu)Q2035Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)Q2036Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)Q2037Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)Q2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)Q2039Influenza virus vaccine, not otherwise specifiedQ2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionQ2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mgQ2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mgQ2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)